Genmab A/S (GMAB) Earnings History
Annual and quarterly earnings data from 2002 to 2024
Loading earnings history...
GMAB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GMAB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 95.4% | 31.1% | 36.4% |
| 2023 | 98.6% | 32.3% | 26.4% |
| 2022 | 100.0% | 43.2% | 37.6% |
| 2021 | 100.0% | 35.1% | 35.1% |
| 2020 | 100.0% | 62.4% | 47.1% |
Download Data
Export GMAB earnings history in CSV or JSON format
Free sign-in required to download data
Genmab A/S (GMAB) Earnings Overview
As of May 6, 2026, Genmab A/S (GMAB) reported trailing twelve-month net income of $6.57B, reflecting +83.9% year-over-year growth. The company earned $10.58 per diluted share over the past four quarters, with a net profit margin of 36.4%.
Looking at the long-term picture, GMAB's 5-year EPS compound annual growth rate (CAGR) stands at +29.0%, indicating exceptional earnings growth. The company achieved its highest annual net income of $7.84B in fiscal 2024, representing a new all-time high.
Genmab A/S maintains industry-leading profitability with a gross margin of 95.4%, operating margin of 31.1%, and net margin of 36.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), SRPT (-$272M net income, 12.4% margin), INCY ($1.43B net income, 25.0% margin), GMAB has outperformed on profitability metrics. Compare GMAB vs REGN →
GMAB Earnings vs Peers
Earnings metrics vs comparable public companies
GMAB Historical Earnings Data (2002–2024)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $7.84B | +80.2% | $6.70B | $12.14 | 36.4% | 31.1% |
| 2023 | $4.35B | -20.2% | $5.32B | $6.60 | 26.4% | 32.3% |
| 2022 | $5.45B | +84.4% | $6.27B | $8.26 | 37.6% | 43.2% |
| 2021 | $2.96B | -37.9% | $2.95B | $4.48 | 35.1% | 35.1% |
| 2020 | $4.76B | +119.7% | $6.31B | $7.22 | 47.1% | 62.4% |
| 2019 | $2.17B | +47.1% | $2.64B | $3.40 | 40.4% | 49.2% |
| 2018 | $1.47B | +33.4% | $1.38B | $2.37 | 48.7% | 45.6% |
| 2017 | $1.10B | -7.0% | $1.34B | $1.78 | 46.7% | 56.8% |
| 2016 | $1.19B | +55.5% | $1.05B | $1.92 | 65.4% | 58.0% |
| 2015 | $764M | +153.4% | $730M | $1.26 | 67.4% | 64.5% |
Full GMAB Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GMAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
Is GMAB growing earnings?
GMAB EPS is $10.58, with earnings growth accelerating to +83.9%. This exceeds the 5-year CAGR of +29.0%. TTM net income reached $6.6B.
What are GMAB's profit margins?
Genmab A/S net margin is +36.4%, with operating margin at +31.1%. Above-average margins indicate pricing power.
How consistent are GMAB's earnings?
GMAB earnings data spans 2002-2024. The accelerating earnings trend is +83.9% YoY. Historical data enables comparison across business cycles.